Exane Derivatives Amicus Therapeutics, Inc. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Exane Derivatives holds 90 shares of FOLD stock, worth $862. This represents 0.0% of its overall portfolio holdings.
Number of Shares
90
Previous 90
-0.0%
Holding current value
$862
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding FOLD
# of Institutions
311Shares Held
312MCall Options Held
516KPut Options Held
833K-
Vanguard Group Inc Valley Forge, PA28.8MShares$276 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY28.1MShares$269 Million7.83% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$233 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA24MShares$230 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY23.2MShares$222 Million3.72% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $2.69B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...